BioMerieux SA has acquired Hyglos GmbH to further develop its approaches in the detection of endotoxins within pharmaceutical products.
The sale consideration of the acquisition is $26.7m, which will be paid in phases over the next three years.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the agreement, Hyglos has been merged and consolidated into BioMerieux’s financial statements effective from 1 June 2016.
Recordati S.p.A plans to expand and strengthen its gastroenterology portfolio through its recent acquisition of 100% shares of Italchimici S.p.A.
The purchase consideration of the transaction is $145m, which has been funded from the existing facilities.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
